Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | USP1 | O94782 | 2/20 | 0.44 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786723 | 0.90 | CYP1A2 (0.45) | GSK3AGSK3BMAPTKDM4EMAPK1 | |
| SCHEMBL12303146 | 0.86 | GSK3A (0.59) | GSK3AGSK3BMAPTKDM4EMAPK1 | |
| SCHEMBL11917652 | 0.85 | CYP1A2 (0.41) | GSK3AGSK3BMAPTKDM4EMAPK1 | |
| SCHEMBL12619831 | 0.84 | GSK3A (0.48) | GSK3AGSK3BUSP1WDR48FADS1 | |
| SCHEMBL785933 | 0.84 | USP1 (0.46) | GSK3AGSK3BMAPTKDM4EUSP1 | |
| SCHEMBL13854196 | 0.84 | GSK3A (0.57) | GSK3AGSK3BMAPTKDM4EMAPK1 | |
| SCHEMBL10267576 | 0.82 | FADS1 (0.47) | GSK3AGSK3BMAPTKDM4EUSP1 | |
| SCHEMBL786256 | 0.82 | USP1 (0.64) | MAPTKDM4EUSP1WDR48MEN1 | |
| SCHEMBL12303145 | 0.81 | USP1 (0.46) | GSK3AGSK3BMAPTKDM4EUSP1 | |
| SCHEMBL12303151 | 0.81 | PIP4K2C (0.45) | MAPTKDM4EUSP1WDR48MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872129-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872129-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872129-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1739087-A1 | Pyrazole compositions useful as inhibitors of gsk-3 | Vertex Pharmaceuticals Incorporated (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1532145-B1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMA (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885MAPT 570/4885 |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | GSK3A, GSK3B, GSKIP | GSK3A 1/4885GSK3B 2/4885MAPT 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.